Acrivon Therapeutics, Inc. ACRV 深 滬
交易中 09-19 12:01:35 美东时间
7.64
+0.080
+1.06%
華盛通- 最 高7.85
- 今 開7.85
- 成交量 5.36万股
- 最 低 7.40
- 昨 收 7.56
- 總市值 1.70亿
- 52周最高 11.90
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 3.19
- 委 比 -92.36%
- 總股本 2219.43万
- 歷史最高 25.47
- 量 比 0.62
- 振 幅 5.95%
- 歷史最低 3.19
- 每 手 1
- 風險率 1.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $22 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $22 price target.
08-14 02:35
Acrivon Therapeutics GAAP EPS of -$0.52
Acrivon Therapeutics press release (NASDAQ:ACRV): Q2 GAAP EPS of -$0.52. As of June 30, 2024, the company had cash, cash equivalents and marketable securities of $220.4 million, More on Acrivon Therap...
08-13 21:51
快讯 | Acrivon Therapeutics公司的现金、现金等价物预计能够支持营业费用和资本支出需求至2026年下半年。
Acrivon Therapeutics Inc- Cash, Cash Equivalents Expected to Fund Operating Exp...
08-13 20:02
快讯 | Acrivon Therapeutics，Inc第二季度营业费用为2143.7万美元。
Acrivon Therapeutics, Inc Q2 Operating Expenses USD 21.437 Million
08-13 20:00
快讯 | Acrivon Therapeutics，Inc第二季度基本每股收益为-0.52美元。
Acrivon Therapeutics, Inc Q2 Basic EPS USD -0.52
08-13 20:00
快讯 | Acrivon Therapeutics报告2024年第二季度财务业绩和业务亮点
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business...
08-13 20:00
HC Wainwright & Co.：维持Acrivon Therapeutics(ACRV.US)评级，由买入调整至买入评级, 目标价由20.00美元调整至22.00美元。
HC Wainwright & Co.：维持Acrivon Therapeutics(ACRV.US)评级，由买入调整至买入评级, 目标价由20.00美...
05-15 01:21
Acrivon Therapeutics Q1 EPS $(0.73) Beats $(0.84) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.84) by 13.1 percent. This is a 25.86 percent decrease over losses of $(0.58) per share
05-14 20:33
Acrivon Therapeutics(ACRV.US)：2024年Q1财报实现营收0美元，前值为0美元；每股收益为-0.73美元，前值为-0.58美元，预期值为-0.84美元。
Acrivon Therapeutics(ACRV.US)：2024年Q1财报实现营收0美元，前值为0美元；每股收益为-0.73美元，前值为-0.58美元，预期...
05-14 08:11
Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral
Ladenburg Thalmann analyst Aydin Huseynov downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Neutral.
04-29 21:12
